Open AccessThrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
Author(s) -
Nilles Kathy M.,
Caldwell Stephen H.,
Flamm Steven L.
Publication year - 2019
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1423
Subject(s) - thrombopoietin , medicine , thrombopoietin receptor , platelet transfusion , platelet , intensive care medicine , eltrombopag , disease , immune thrombocytopenia , haematopoiesis , genetics , stem cell , biology
Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost. No other short‐term options for ameliorating thrombocytopenia before procedures were available until the thrombopoietin receptor agonists were recently approved. Avatrombopag and lusutrombopag can be used in certain patients with thrombocytopenia due to advanced liver disease undergoing elective invasive procedures; these new agents are highly effective in carefully selected patients, and real world data of safety and efficacy are awaited.